Deep Creek Pharma LLC
Yadkinville, NC
- UEI
- K3KKUWLAKDE3
- CAGE
- 8G9W4
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1445 Crater Ln, Yadkinville, NC 27055, USA
- Website
- deepcreekpharma.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Modified thrombin binding aptamer treatment of CRC metastasis - project summary metastatic colorectal cancer (mcrc)… | National Cancer Institute | $399,968 | |
| Improved treatment of colorectal cancer with CF10 - project summary decades of modulating the anti-cancer activity of… | National Cancer Institute | $2,947,475 | |
| Improved treatment of colorectal cancer with CF10 diversity supplement - project summary for supplement to CA254834 this… | National Cancer Institute | $1,398,263 |
About Deep Creek Pharma LLC
Deep Creek Pharma LLC is a small disadvantaged business located in Yadkinville, North Carolina, registered in SAM.gov since December 20, 2019, with registration valid through March 27, 2026. As a for-profit corporate entity, the company appears to specialize in developing innovative pharmaceutical and therapeutic solutions, with a primary focus on cancer treatment research. Their work primarily involves advanced nanoscale material development and molecular engineering targeting cancer treatment, particularly colorectal cancer therapies.
The company has received multiple project grants from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), focusing on developing novel therapeutic approaches for metastatic colorectal cancer. Their research has centered on two primary innovations: TBAEFPREX, a modified thrombin-binding aptamer designed to target cancer cells with high cytotoxicity, and CF10, a DNA-based fluoropyrimidine polymer that demonstrates improved potency and reduced systemic toxicity compared to traditional 5-fluorouracil (5-FU) treatments. Deep Creek Pharma collaborates closely with Wake Forest University Health Sciences and Wake Forest School of Medicine, leveraging academic partnerships to advance their research. Their grant-funded projects have explored developing lipid nanoparticle formulations, investigating anti-metastatic activities in various colon tumor models, and creating more effective treatment strategies for patients with metastatic colorectal cancer that is resistant to conventional therapies.
Quick answers
What is Deep Creek Pharma LLC's UEI?
Deep Creek Pharma LLC's Unique Entity ID (UEI) in SAM.gov is K3KKUWLAKDE3.
What is Deep Creek Pharma LLC's CAGE code?
Deep Creek Pharma LLC's CAGE code is 8G9W4.
What is Deep Creek Pharma LLC's primary NAICS code?
Deep Creek Pharma LLC's primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Where is Deep Creek Pharma LLC located?
Deep Creek Pharma LLC's physical address in SAM.gov is 1445 Crater Ln, Yadkinville, NC 27055, USA.
Is Deep Creek Pharma LLC registered in SAM.gov?
Yes. Deep Creek Pharma LLC's SAM.gov registration is active through June 18, 2027.
What is Deep Creek Pharma LLC's most recent federal award?
Deep Creek Pharma LLC's most recent federal grant award is Modified thrombin binding aptamer treatment of CRC metastasis - project summary metastatic colorectal cancer (mcrc)… (R41CA302074), from National Cancer Institute, on September 2, 2025.
On GovTribe
See Deep Creek Pharma LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors